Navigation Links
Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
Date:1/29/2013

BRIDGEWATER, N.J., Jan. 29, 2013 /PRNewswire/ -- Sanofi US announced the commercial launch of LeGoo®, a biopolymer gel that allows surgeons to temporarily stop blood flow during surgery without the use of clamps, elastic loops or other conventional occlusion devices, which may increase risk of trauma to blood vessels. The atraumatic occlusion technique potentially provides clear visualization with less clutter while maintaining vessel integrity. The announcement was made in conjunction with this year's annual Society of Thoracic Surgeons (STS) Meeting, which is being held in Los Angeles this week.

To view the multimedia assets, please click: http://www.multimedianewscenter.com/biosurgerylegoo/legoo-full-commercial-availability

As the first and only atraumatic intraluminal occlusion gel, LeGoo is injected into a blood vessel and forms a plug that molds to the shape of the vessel, stopping blood flow temporarily. The plug custom-adapts to the contour of each individual blood vessel, delivering a truly sophisticated approach to surgical procedures.  Upon completion of the anastomosis, LeGoo is dissolved spontaneously in about 15 minutes or by cooling the vessel directly through ice application or cold saline infusion, which restores blood flow.

"LeGoo represents an elegantly simple and atraumatic solution to temporary vessel occlusion," David H. Deaton , MD FACS, Chief, Vascular and Endovascular Surgery, MedStar Georgetown University Hospital. "The fluid nature of LeGoo adapts to any arterial anatomy irrespective of shape or calcific disease, delivering a truly sophisticated and flexible approach to vascular anastomoses and providing a clear surgical field.  LeGoo is an innovative advance in cardiovascular surgery."

<
'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
2. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
3. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
4. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
5. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
6. Sanofi Pasteur to add 2D barcode to six more vaccines
7. Sanofi US Launches Collaborate Activate Innovation Challenge
8. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
9. New Website IVT Network Launches Today for Validation and Compliance Professionals
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. Sequent Medical, Inc. Launches VIA Microcatheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... 2014 Trovagene, Inc. (NASDAQ:   TROV), a ... from two clinical studies will be presented at the ... diagnostic test for the detection of high risk strains ... to take place in Seattle ... Additionally, a new U.S. patent was issued earlier this ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... announces that a new market research report is ... Degeneration Therapy Area Pipeline Report ... Therapy Area Pipeline Report contains detailed information on ... insight into the pipeline status of macular degeneration ...
... Allscripts (NASDAQ: MDRX ) announced today that it ... March 31, 2011 after the stock market closes on Thursday, ... and webcast to discuss the company,s earnings and other information ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) More ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... and other minor infections might trigger a strong but brief ... study suggests. Just five out of 100,000 children a ... Heather Fullerton, lead author of the study and a professor ... Francisco Benioff Children,s Hospital. "It seems infections play a role ...
(Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... reconstruction after a mastectomy has long been an option, but ... women choose it. "The most common reasons women didn,t ... weren,t interested in more surgery or they were focused on ... of breast surgery at Memorial Sloan Kettering Cancer Center, in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... of Pittsburgh School of Medicine. , Their findings, published ... acute hemodialysis, an aggressive method that is standardly used ... a definitive benefit to the patient. , "Our findings ...
(Date:8/20/2014)... approach to treating cancer - using Botox. A study ... Translational Medicine shows that cancer growth could be ... are linked to cancer stem cells. The approach thus ... treatment cheap, safe and efficient. The researchers have thus ... start testing on humans. , The nervous system is ...
(Date:8/20/2014)... Pittsburgh, PA (PRWEB) August 20, 2014 ... waste products from the blood did not improve survival ... an analysis led by experts at the University ... findings, published online today in the journal PLOS ... is standardly used for people with sudden kidney failure, ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
... Pakistan Tuesday enhanced their cooperation in the crucial area ... polio and avian flu. // ,"The ... exchanged ideas on management of avian influenza," external affairs ... the first meeting of the India-Pakistan Joint Commission technical-level ...
... over reports of malarial deaths in Jharkhand's Sahibganj district, the ... // , today urged the health department to step up ... at the earliest direct its medical teams to find out ... disease has afflicted several people in the district, JD(U) spokesman ...
... A recent study has revealed that the place of birth determines ... far lower life expectancy than those born in south east England ... city was found to be 69.3 it was found to be ... conducted the research and it has ranked the 10 best and ...
... insisted that hospital consultants who are not referring patients to ... concerns that the NTPF has only seen a fraction of ... ,NTPF chairman Pat O'Byrne commented that there was no ... months for a surgical procedure. ,"There's no doubt ...
... Boards (DHBs), striking junior doctors returned to hospital calling off their ... doctor's union - Resident Doctors' Association (RDA) and the DHBs met ... planned to meet on Thursday for confirming the results. ... lasted for 5 days. , ,But unfortunately last time ...
... Carolina have found that very few of the patients ... resulted due to chronic obstructive pulmonary disease (COPD) such ... and management. ,Explaining that ideal care means ... the treatment guidelines for this condition and none of ...
Cached Medicine News:Health News:Life Expectancy Determined by Place of Birth 2Health News:COPD Patients In US Are Not Receiving 'Ideal Care' 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: